To investigate whether high perceived stress is associated with inflammatory reprogramming of innate immune cells and their bone marrow progenitors, and with increased arterial wall inflammation, in subjects with an increased CVD risk.
ID
Source
Brief title
Condition
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis
Synonym
Research involving
Sponsors and support
Intervention
- No intervention
N.a.
Outcome measures
Primary outcome
<p>All 125 included patients will fill out questionnaires and donate blood. In the<br />
subgroup of 25 patients with highest and lowest perceived stress according to<br />
the PSS10 questionnaire, we will also perform 18F-fluorodeoxyglucose<br />
(FDG)-Positron Emission Tomography (PET)/CT scanning, and isolate hematopoietic<br />
and progenitor cells (HSPCs) from the peripheral blood. The primary outcome is<br />
the ex vivo production of TNF by isolated Peripheral Blood Mononuclear Cells<br />
(PBMCs). </p>
Secondary outcome
<p>Additional study parameters are flow cytometry, and (single cell) RNA and ATAC<br />
sequencing of circulating immune cells and circulating HSPCs, and FDG-uptake in<br />
the arterial wall and bone marrow.</p>
Background summary
Cardiovascular diseases (CVD), including stroke, myocardial infarction, and
peripheral arterial disease, are the main cause of mortality worldwide. The
majority of CVD is caused by atherosclerosis, which is a chronic low-grade
inflammatory disorder of the arterial wall. Innate immune cells, including
monocytes and macrophages, importantly contribute to the pathophysiology of
atherosclerosis.
In this study, we will investigate the effects of perceived psychosocial stress
on the innate immune system and arterial wall inflammation in patients with
heightened risk for CVD. Epidemiological studies have well-established that
psychosocial stress is an independent risk factor for atherosclerotic CVD. The
exact mechanism mediating this association, however, remains incompletely
understood. Preclinical studies have suggested that stress leads to a prolonged
hyperresponsiveness of innate immune cells by (epigenetic) reprogramming of
their progenitor cells, but this has never been tested in humans.
Study objective
To investigate whether high perceived stress is associated with inflammatory
reprogramming of innate immune cells and their bone marrow progenitors, and
with increased arterial wall inflammation, in subjects with an increased CVD
risk.
Study design
An observational cross-sectional study.
Intervention
none
Study burden and risks
Participants will not benefit from participating in this study. With their
participation they
can help the researchers to gain more insight into how stress can predispose
individuals to CVD. This will not only enhance our understanding of how stress
affects atherosclerotic CVD, but could also unveil potential novel treatment
targets to lower CVD risk in patients at high stress levels.
Potential risks are described below for all procedures separately.
• Blood draw: In total 52 ml blood will be obtained, which is not expected to
result in side effects. Risks of vena puncture are hematoma formation and minor
pain. This will be minimized by having vena puncture performed by experienced
nurses or physicians.
We thus feel that the risks and burdens to the subjects are proportional to the
potential value of this study, which will deliver ground breaking insight into
the mechanisms of how trained immunity is induced the context of psychosocial
stress. Duration of the procedure: 10 minutes.
• FDG PET-CT imaging The PET/CT scan will result in an effective radiation
dose of 3.0 (PET) + 5.2 (CT) = 8.2 mSv (also see Radiation Ethics Form). In
line with Risk Category IIb, the proposed study will significantly contribute
to increased knowledge on how stress can affect CVD by impacting on the immune
system, by a process named trained immunity. This mechanism contributes to the
subsequent acceleration of atherosclerosis throughout the body and subsequent
cardiovascular events. Knowledge on this mechanism and on how this mechanism
can be non-invasively detected by PET scanning, will contribute to the
development of novel pharmacological strategies to reduce cardiovascular
disease. Given the potential benefits or our results, we think this radiation
exposure is proportional.
Duration of the procedure: 4 hours.
N. P. Riksen
Geert Grooteplein Zuid 8
Nijmegen 6525 GA
Netherlands
0243618819
niels.riksen@radboudumc.nl
N. P. Riksen
Geert Grooteplein Zuid 8
Nijmegen 6525 GA
Netherlands
0243618819
niels.riksen@radboudumc.nl
Trial sites in the Netherlands
Listed location countries
Age
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all
of the following criteria:
- Age 40-70 years
- Heightened cardiovascular risk, defined as a) a moderate to high risk for CVD
(>5% 10 year ASCVD risk, according to American College of Cardiology (ACC)
AtheroSclerotic Cardiovascular Disease (ASCVD) risk calculator
(https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/) or b)
subclinical ASCVD on imaging (e.g. elevated CAC or asymptomatic
coronary artery stenosis), or c) a LDL-c concentration > 4.9 mmol/l.
- Written informed consent
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
• Previous cardiovascular events (stroke, TIA, myocardial infarction, coronary revascularization, aortic aneurysm, peripheral arterial disease)
• Heart failure
• Auto-inflammatory or auto-immune diseases
• Use of immunomodulating drugs
• Severe renal failure (MDRD <30)
• Previous vaccination within 1 months prior to study entry.
• Current infection or clinically significant infections within 1 months before
participation (defined as fever >38.5).
• Pregnancy/lactation
• Severe psychiatric disorder.
• Inability to undergo PET-CT scanning
• History of hematological malignant disease
• Documented bleeding diathesis or thrombocytopenia <50 *10e9/L
Design
Recruitment
Medical products/devices used
IPD sharing statement
Plan description
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL84802.091.23 |
Research portal | NL-005042 |